Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes

Biochemical Pharmacology

Volumn 91, Issue 3, 2014, Pages 312-322

  Ishiguro, Kimiko ^a   Lin, Z Ping ^b   Penketh, Philip G ^b   Shyam, Krishnamurthy ^b   Zhu, Rui ^b   Baumann, Raymond P ^b   Zhu, Yong Lian ^b   Sartorelli, Alan C ^b   Rutherford, Thomas J ^a   Ratner, Elena S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

DNA double strand breaks; DNA replication stress; Dp44mT (di 2 pyridylketone 4 4 dimethyl 3 thiosemicarbazone); Metal coordination; Reactive oxygen species; Triapine (3 AP,3 aminopyridine 2 carboxaldehyde thiosemicarbazone)

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; COBALT; COPPER COMPLEX; COPPER ION; CUPRIC ION; DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; DOUBLE STRANDED DNA; FERRIC ION; FERROUS ION; HYDROXYUREA; MANGANESE; NICKEL; REACTIVE OXYGEN METABOLITE; THIOL DERIVATIVE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; ZINC ION; 2-FORMYLPYRIDINE THIOSEMICARBAZONE; 3-AMINOPYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONE; COPPER; DI-2-PYRIDYLKETONE-4,4-DIMETHYL-3-THIOSEMICARBAZONE; ENZYME; H2AFX PROTEIN, HUMAN; HISTONE; PYRIDINE DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CULTURE; CELL DEATH; CELL KILLING; CELL SURVIVAL; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA REPLICATION; DNA SYNTHESIS; DOUBLE STRANDED DNA BREAK; DRUG EXPOSURE; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; ENZYME INHIBITION; FEMALE; GROWTH INHIBITION; HL 60 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LC50; LEUKEMIA P 388; MCF 7 CELL LINE; NONHUMAN; OVARIAN CANCER CELL LINE; OXIDATIVE STRESS; PRIORITY JOURNAL; STOICHIOMETRY; DRUG EFFECTS; METABOLISM; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; COPPER; DNA BREAKS, DOUBLE-STRANDED; ENZYMES; HISTONES; HL-60 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; PYRIDINES; THIOSEMICARBAZONES; TIME FACTORS;

EID: 84925457777     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.08.006     Document Type: Article

References (49)

1. Yu Y, Kalinowski DS, Kovacevic Z, Siafakas AR, Jansson PJ, Stefani C, et al. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem 2009;52:5271-94.
2. Pahl PM, Horwitz LD. Cell permeable iron chelators as potential cancer chemotherapeutic agents. Cancer Invest 2005;23:683-91.
3. Gupte A, Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev 2009;35:32-46.
4. Liu MC, Lin TS, Sartorelli AC. Synthesis and antitumor activity of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone. J Med Chem 1992;35:3672-7.
5. Liu MC, Lin TS, Sartorelli AC. Chemical and biological properties of cytotoxic a-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Prog Med Chem 1995;32:1-35.
6. Finch RA, Liu MC, Cory AH, Cory JG, Sartorelli AC. Triapine (3-aminopyridine-2- carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv Enzyme Regul 1999;39:3-12.
7. Finch RA, Liu M, Grill SP, Rose WC, Loomis R, Vasquez KM, et al. Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 2000;59:983-91.
8. Sartorelli AC, Agrawal KC, Tsiftsoglou AS, Moore EC. Characterization of the biochemical mechanism of action of a-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Adv Enzyme Regul 1976;15:117-39.
9. Moore EC, Sartorelli AC. Inhibition of ribonucleotide reductase by a-(N)- heterocyclic carboxaldehyde thiosemicarbazones. Pharmacol Ther 1984;24: 439-47.
10. Cory JG, Cory AH, Rappa G, Lorico A, Liu MC, Lin TS, et al. Structure-function relationships for a new series of pyridine-2-carboxaldehyde thiosemicarbazones on ribonucleotide reductase activity and tumor cell growth in culture and in vivo. Adv Enzyme Regul 1995;35:55-68.
11. Nordlund P, Reichard P. Ribonucleotide reductases. Annu Rev Biochem 2006;75:681-706.
12. Cotruvo JA, Stubbe J. Class I ribonucleotide reductases: metallocofactor assembly and repair in vitro and in vivo. Annu Rev Biochem 2011;80:733-67.
13. Shao J, Liu X, Zhu L, Yen Y. Targeting ribonucleotide reductase for cancer therapy. Expert Opin Ther Targets 2013;17:1423-37.
14. Cerqueira NM, Fernandes PA, Ramos MJ. Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents. Recent Pat Anti-cancer Drug Discov 2007;2:11-29.
15. Yuan J, Lovejoy DB, Richardson DR. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 2004;104:1450-8.
16. Richardson DR, Sharpe PC, Lovejoy DB, Senaratne D, Kalinowski DS, Islam M, et al. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J Med Chem 2006;49:6510-21.
17. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A 2006;103:14901-06.
18. Lovejoy DB, Sharp DM, Seebacher N, Obeidy P, Prichard T, Stefani C, et al. Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo. J Med Chem 2012;55:7230-44.
19. Kowol CR, Trondl R, Heffeter P, Arion VB, Jakupec MA, Roller A, et al. Impact of metal coordination on cytotoxicity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine) and novel insights into terminal dimethylation. J Med Chem 2009;52:5032-43.
20. Brockman RW, Thomson JR, Bell MJ, Skipper HE. Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone. Cancer Res 1956;16:167-70.
21. Bernhardt PV, Sharpe PC, Islam M, Lovejoy DB, Kalinowski DS, Richardson DR. Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity. J Med Chem 2009;52:407-15.
22. Popovic-Bijelic A, Kowol CR, Lind ME, Luo J, Himo F, Enyedy EA, et al. Ribonucleotide reductase inhibition by metal complexes of triapine (3-aminopyridine- 2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study. J Inorg Biochem 2011;105:1422-31.
23. Kowol CR, Heffeter P, Miklos W, Gille L, Trondl R, Cappellacci L, et al. Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds. J Biol Inorg Chem 2012;17:409-23.
24. Lin ZP, Lee Y, Lin F, Belcourt MF, Li P, Cory JG, et al. Reduced level of ribonucleotide reductase R2 subunits increases dependence on homologous recombination repair of cisplatin-induced DNA damage. Mol Pharmacol 2011;80:1000-12.
25. Fugger K, Chu WK, Haahr P, Kousholt AN, Beck H, Payne MJ, et al. FBH1 co-operates with MUS81 in inducing DNA double-strand breaks and cell death following replication stress. Nat Commun 2013;4:1423-30.
26. Sundquist WI, Ahmed KJ, Hollis LS, Lippard SJ. Solvolysis reactions of cis- and trans-diamminedichloroplatinum(II) in dimethyl sulfoxide. Structural characterization and DNA binding of trans-[Pt(NH3)2(Me2SO)Cl]+. Inorg Chem 1987;26:1524-8.
27. Collins SJ, Gallo RC, Gallagher RE. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature 1977;270: 347-9.
28. Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, Lessey BA, et al. DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol 2012;127:241-8.
29. Ishiguro K, Zhu YL, Shyam K, Penketh PG, Baumann RP, Sartorelli AC. Quantitative relationship between guanine O6-alkyl lesions produced by Onrigin and tumor resistance by O6-alkylguanine-DNA alkyltransferase. Biochem Pharmacol 2010;80:1317-25.
30. Lin ZP, Ratner ES, Whicker ME, Lee Y, Sartorelli AC. Triapine disrupts CtIPmediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors. Mol Cancer Res 2014;12:381-93.
31. Ishiguro K, Sartorelli AC. Activation of transiently transfected reporter genes in 3T3 Swiss cells by the inducers of differentiation/apoptosis - dimethylsulfoxide, hexamethylene bisacetamide and trichostatin A. Eur J Biochem 2004;271:2379-90.
32. Ishiguro K, Seow HA, Penketh PG, Shyam K, Sartorelli AC. Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine. Mol Cancer Ther 2006;5:969-76.
33. Jansson PJ, Sharpe PC, Bernhardt PV, Richardson DR. Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity. J Med Chem 2010;53:5759-69.
34. Lovejoy DB, Jansson PJ, Brunk UT, Wong J, Ponka P, Richardson DR. Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res 2011;71:5871-80.
35. Merlot AM, Kalinowski DS, Richardson DR. Novel chelators for cancer treatment: where are we now. Antioxid Redox Signal 2013;18:973-1006.
36. Yu Y, Suryo Rahmanto Y, Hawkins CL, Richardson DR. The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4,4-dimethyl-3-thiosemi- carbazone and 2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity. Mol Pharm 2011;79:921-31.
37. Gaal A, Orgovan G, Polgari Z, Reti A, Mihucz VG, Bosze S, et al. Complex forming competition and in-vitro toxicity studies on the applicability of di-2-pyridylketone- 4,4,-dimethyl-3-thiosemicarbazone (Dp44mT) as a metal chelator. J Inorg Biochem 2014;130:52-8.
38. Gomez-Saiz P, Garcia-Tojal J, Diez-Gomez V, Gil-Garcia R, Pizarro JL, Arriortua MI, et al. Indirect evidences of desulfurization of a thiosemicarbazoneopper(II) system in aqueous basic medium. Inorg Chem Commun 2005;8:259-62.
39. Hogness TR, Johnson WC. In qualitative analysis and chemical equilibrium. New York: Holt, Rinehart and Winston, Inc; 1954. 565.
40. Enyedy EA, Nagy NV, Zsigo E, Kowol CR, Arion VB, Keppler BK, et al. Comparative solution equilibrium study of the interactions of copper(II), iron(II) and zinc(II) with triapine (3-aminopyridine-2-carbaldehyde thiosemicarbazone) and related ligands. Eur J Inorg Chem 2010;2010:1717-28.
41. Shao J, Zhou B, Di Bilio AJ, Zhu L, Wang T, Qi C, et al. A ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol Cancer Ther 2006;5:586-92.
42. Aye Y, Long MJ, Stubbe J. Mechanistic studies of semicarbazone triapine targeting human ribonucleotide reductase in vitro and in mammalian cells: tyrosyl radical quenching not involving reactive oxygen species. J Biol Chem 2012;287:35768-78.
43. Held KD, Biaglow JE. Mechanisms for the oxygen radical-mediated toxicity of various thiol-containing compounds in cultured mammalian cells. Radiat Res 1994;139:15-23.
44. Hancock CN, Stockwin LH, Han B, Divelbiss RD, Jun JH, Malhotra SV, et al. A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo. Free Radic Biol Med 2011;50:110-21.
45. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2011;475:231-4.
46. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012;149:1060-72.
47. Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, et al. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res 2006;30:813-22.
48. Kunos CA, Radivoyevitch T, Waggoner S, Debernardo R, Zanotti K, Resnick K, et al. Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers. Gynecol Oncol 2013;130:75-80.
49. Feun L, Modiano M, Lee K, Mao J, Marini A, Savaraj N, et al. Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chemother Pharmacol 2002;50:223-9.